



**Sinclair Pharma Strengthens Board
Grahame Cook appointed as Non Executive Director**

Godalming, UK; 12 July, 2004: Sinclair Pharma plc (“Sinclair” and the “Company”), the pharmaceutical company focused on the acquisition, development and out-licensing of niche patented products, today announces the appointment of Grahame Cook as non-executive director with immediate effect.

Grahame, aged 46, has over 18 years in investment banking advising on a wide range of M&A and Capital Market transactions in the US and Europe. He was until recently, Global CEO of West LB Panmure, where he joined in 1999. Prior to that, from 1995, Grahame was Managing Director of Capital Markets and on the Global Investment Banking Management Committee at UBS.

Grahame’s earlier career includes six years as Director of Barclays de Zoete Wedd Corporate Finance, and seven years as a chartered accountant at Arthur Anderson. He has advised on a number of transactions in the pharmaceutical and biotechnology sectors across Europe and the US, including private equity investments, IPOs and secondary offerings. Grahame was a founder member of the LSE’s TechMARK Advisory Committee, and holds an MA, double first, from Oxford University.

Commenting on the appointment, Steve Harris, Chairman of Sinclair Pharma, said: “I am delighted to welcome Grahame to the Board of Sinclair. Grahame brings invaluable capital markets and industry experience, he will be a great asset to Sinclair as we advance the Company and pipeline.”

ENDS

Contact details:

Sinclair Pharma plc

Dr Michael Flynn, CEO

Tel: 01483 426 6444

Financial Dynamics

Ben Atwell, Lucy Briggs

Tel: 0207 269 7242

"Safe Harbor" Statement under the US Private Securities Litigation Reform Act of 1995: Some or all of the statements in this document that relate to future plans, expectations, events, performances and the like are forward-looking statements, as defined in the US Private Securities Litigation Reform Act of 1995. Actual results of events could differ materially from those described in the forward- looking statements due to a variety of factors.

Notes to Editors

Sinclair Pharma plc is an international pharmaceutical company focused on the acquisition and development of niche patented products in the fields of oral health, oncology support and dermatology and brings them to the international market place. The Company combines product evaluation, product development, regulatory and business development expertise to add value to its acquired and in-house developed products. A key element of the Sinclair business model is to minimise risk and exposure by avoiding involvement in lengthy R&D programmes and rapidly achieving global distribution through a network of marketing partners. The Company has already licensed distribution in over 40 countries for the Group's products.

www.sinclairpharma.com